| abstract |
Modulators such as proteins, peptides, antibodies or analogs, fragments or derivatives of any of them are provided which are capable of interacting with, or binding to, the intracellular domain of the membrane-bound form of TNF (26 KD TNF). These modulators are capable or regulating the expression, proteolytic processing, bioactivity or intracellular signaling of the 26 KD TNF and may thus be used for the treatment of diseases in which TNF plays a central role. |